Healthcare Aug 30, 2021 03:09 PM (GMT+8) · EqualOcean
According to the announcement on the official website of the State Food and Drug Administration of China, the anti-PD-1 all human monoclonal antibody drug gls-010 injection (cyprimab) developed by Yaoming biology entrusted by Yuheng biology, a joint-stock company of Yuheng pharmaceutical industry, has been approved for listing. The drug submitted a new drug marketing application in China in January 2020. The first indication of the application is recurrent or refractory classical Hodgkin's lymphoma (CHL).